{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:03:50Z","timestamp":1789625030857,"version":"build-2803163510"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the recent therapeutic advances, approximately one-third of patients with chronic migraine fail to achieve clinically meaningful benefit, and existing oral preventive therapies remain limited by tolerability and off-target effects. There is, therefore, a pressing need for new, well-tolerated, mechanistically distinct preventive treatments for chronic migraine. This hypothesis article evaluates the pharmacological and biological rationale supporting guanfacine as a potential preventive therapy for chronic migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>We hypothesize that guanfacine, a selective \u03b12A-adrenergic receptor agonist already approved for hypertension and attention-deficit\/hyperactivity disorder, may have the potential to prevent chronic migraine through three biologically plausible convergent mechanisms: (1) potential presynaptic inhibition of calcium-dependent release of CGRP, glutamate, substance P, and other pro-nociceptive neuropeptides from trigeminal primary afferents; (2) potential attenuation of peripheral and central sensitization within the trigeminovascular system and the trigeminocervical complex; and (3) potential modulation of descending pain control pathways arising from the locus coeruleus and prefrontal cortex. This hypothesis is supported by evidence linking the ADRA2B gene to trigeminal nerve disorders, by recently published randomized controlled trial data demonstrating enhanced analgesia when guanfacine is added to lidocaine for trigeminal nerve blocks, and by the established analgesic activity of related \u03b12-adrenergic agonists in neuropathic pain. However, it is important to note, direct evidence supporting these mechanisms in migraine treatment is lacking, and the proposed effects are largely based on biological plausibility derived from \u03b12-adrenergic receptor pharmacology and experimental observations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications<\/jats:title>\n                    <jats:p>Guanfacine has a favorable safety profile and a unique pharmacological signature compared with currently available migraine preventives. Despite indirect evidence presented here, it warrants evaluation in randomized, placebo-controlled trials for chronic migraine prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1947051","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:33:19Z","timestamp":1789623199000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Guanfacine as a potential preventive therapy for chronic migraine: a mechanistic hypothesis"],"prefix":"10.3389","volume":"17","author":[{"given":"Tigran","family":"Kesayan","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Division of Pain Medicine, Vanderbilt University Medical Center","place":["Nashville, TN, United States"]},{"name":"Department of Neurology, Vanderbilt University Medical Center","place":["Nashville, TN, United States"]},{"name":"Department of Plastic Surgery, Vanderbilt University Medical Center","place":["Nashville, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vanderbilt University Medical Center","place":["Nashville, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","article-title":"Migraine","volume":"8","author":"Ferrari","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies: successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"03331024241252666","DOI":"10.1177\/03331024241252666","article-title":"International headache society global practice recommendations for the acute pharmacological treatment of migraine","volume":"44","author":"Puledda","year":"2024","journal-title":"Cephalalgia"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(20)32342-4","article-title":"Migraine: integrated approaches to clinical management and emerging treatments","volume":"397","author":"Ashina","year":"2021","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","article-title":"Erenumab versus topiramate for the prevention of migraine: a randomised, double-blind, active-controlled phase 4 trial","volume":"42","author":"Reuter","year":"2022","journal-title":"Cephalalgia"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1212\/WNL.0000000000207292","article-title":"Late response to anti-CGRP monoclonal antibodies in migraine: a multicenter prospective observational study","volume":"101","author":"Barbanti","year":"2023","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1089\/adt.2019.950","article-title":"Systematically prioritizing candidates in genome-based drug repurposing","volume":"17","author":"Challa","year":"2019","journal-title":"Assay Drug Dev Technol"},{"key":"ref8","first-page":"448","article-title":"Guanfacine extended-release tablets (Intuniv), a nonstimulant selective alpha(2A)-adrenergic receptor agonist for attention-deficit\/hyperactivity disorder","volume":"35","author":"Cruz","year":"2010","journal-title":"P T"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards Subcommittee of the American Academy of neurology and the American headache society","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.7326\/ANNALS-25-02221","article-title":"Effectiveness and tolerability of pharmacologic prophylaxis for chronic migraine: a systematic review of randomized controlled trials","volume":"179","author":"Khalili","year":"2026","journal-title":"Ann Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1474-4422(25)00477-6","article-title":"Advances in migraine prevention","volume":"25","author":"Martinelli","year":"2026","journal-title":"Lancet Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/pm\/pnaf054","article-title":"Enhanced pain relief with guanfacine as an adjuvant for trigeminal nerve blocks: insights from a PheWAS-guided randomized controlled study","volume":"26","author":"Meier","year":"2025","journal-title":"Pain Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol Rev"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/head.13529","article-title":"CGRP and the trigeminal system in migraine","volume":"59","author":"Iyengar","year":"2019","journal-title":"Headache"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2147\/JPR.S329280","article-title":"Central sensitization in migraine: a narrative review","volume":"15","author":"Suzuki","year":"2022","journal-title":"J Pain Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/head.12324","article-title":"Why is guanfacine recommended by AHS and AAN for migraine prevention?","volume":"54","author":"Tfelt-Hansen","year":"2014","journal-title":"Headache"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1212\/WNL.0b013e31822550e2","article-title":"CGRP: sensory neuropeptide with multiple neurologic implications","volume":"77","author":"Benarroch","year":"2011","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s10194-018-0852-4","article-title":"PACAP and its role in primary headaches","volume":"19","author":"Edvinsson","year":"2018","journal-title":"J Headache Pain"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/acps.13817","article-title":"Treatment of early-onset specified and unspecified bipolar disorders: a systematic review and strategies for identifying and managing a thermally dysregulated subtype in children","volume":"152","author":"Papolos","year":"2025","journal-title":"Acta Psychiatr Scand"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.31083\/ph.2010.9697","article-title":"Effects of selective alpha 2-adrenoreceptor stimulation on capsaicin-evoked substance P release from primary cultured dorsal root ganglion neurons","volume":"65","author":"Gong","year":"2010","journal-title":"Pharmazie"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.tins.2024.08.009","article-title":"Neuroimmune interactions in the development and chronification of migraine headache","volume":"47","author":"Zhang","year":"2024","journal-title":"Trends Neurosci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/SPC.0000000000000055","article-title":"Descending pain modulation and chronification of pain","volume":"8","author":"Ossipov","year":"2014","journal-title":"Curr Opin Support Palliat Care"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/j.pain.0000000000001421","article-title":"Divergent influences of the locus coeruleus on migraine pathophysiology","volume":"160","author":"Vila-Pueyo","year":"2019","journal-title":"Pain"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/head.13771","article-title":"Neuromelanin locus coeruleus MRI contrast in migraine with aura","volume":"60","author":"Gollion","year":"2020","journal-title":"Headache"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/jnr.23956","article-title":"The noradrenergic locus coeruleus as a chronic pain generator","volume":"95","author":"Taylor","year":"2017","journal-title":"J Neurosci Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1093\/brain\/awad002","article-title":"A critical brainstem relay for mediation of diffuse noxious inhibitory controls","volume":"146","author":"Kucharczyk","year":"2023","journal-title":"Brain"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","article-title":"Alpha-2 adrenergic receptor agonists: a review of current clinical applications","volume":"62","author":"Giovannitti","year":"2015","journal-title":"Anesth Prog"},{"key":"ref28","first-page":"295","article-title":"The alpha 2-adrenergic agonists clonidine and guanfacine produce tonic and phasic block of conduction in rat sciatic nerve fibers","volume":"76","author":"Butterworth","year":"1993","journal-title":"Anesth Analg"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1038\/sj.bjp.0704032","article-title":"Contribution of alpha(2) receptor subtypes to nerve injury-induced pain and its regulation by dexmedetomidine","volume":"132","author":"Malmberg","year":"2001","journal-title":"Br J Pharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0169-328X(95)00148-L","article-title":"Alpha2-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha2-adrenergic receptor subtypes at four distinct levels","volume":"34","author":"Smith","year":"1995","journal-title":"Brain Res Mol Brain Res"},{"key":"ref31","first-page":"45","article-title":"Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale","volume":"85","author":"Arnsten","year":"2012","journal-title":"Yale J Biol Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/978-3-031-08376-1_33","volume-title":"Hospitalized Chronic Pain Patient: A Multidisciplinary Treatment Guide","author":"MacDougal","year":"2022"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2007.03.015","article-title":"Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex","volume":"129","author":"Wang","year":"2007","journal-title":"Cell"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s43440-023-00458-4","article-title":"Guanfacine inhibits interictal epileptiform events and sodium currents in prefrontal cortex pyramidal neurons","volume":"75","author":"Pasierski","year":"2023","journal-title":"Pharmacol Rep"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMra1914484","article-title":"Trigeminal neuralgia","volume":"383","author":"Cruccu","year":"2020","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","article-title":"Migraine","volume":"391","author":"Dodick","year":"2018","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1007\/s00415-022-11002-4","article-title":"The trigeminal pathways","volume":"269","author":"Terrier","year":"2022","journal-title":"J Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.brainres.2014.11.031","article-title":"Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier","volume":"1600","author":"Eftekhari","year":"2015","journal-title":"Brain Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/s0306-4522(02)00481-5","article-title":"Changes of the excitability of rat trigeminal root ganglion neurons evoked by alpha(2)-adrenoreceptors","volume":"115","author":"Takeda","year":"2002","journal-title":"Neuroscience"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1782719","DOI":"10.1155\/2018\/1782719","article-title":"Dexmedetomidine Inhibits Voltage-Gated Sodium Channels via \u03b12-Adrenoceptors in Trigeminal Ganglion Neurons","volume":"2018","author":"Im","year":"2018","journal-title":"Mediat Inflamm"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.neuropharm.2013.09.024","article-title":"Activation of alpha2 adrenoceptors inhibited NMDA receptor-mediated nociceptive transmission in spinal dorsal horn of mice with inflammatory pain","volume":"77","author":"Fan","year":"2014","journal-title":"Neuropharmacology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1089\/jpm.2013.0556","article-title":"Dexmedetomidine as adjuvant therapy for acute postoperative neuropathic pain crisis","volume":"17","author":"O'Neil","year":"2014","journal-title":"J Palliat Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1046\/j.1526-4610.2002.02122.x","article-title":"Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study","volume":"42","author":"Saper","year":"2002","journal-title":"Headache"},{"key":"ref45","author":"Mao","year":"2023"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1751-7176.2011.00509.x","article-title":"Central sympatholytic drugs","volume":"13","author":"Vongpatanasin","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1600-0404.1978.tb02889.x","article-title":"Clonidine in the prophylaxis of migraine","volume":"58","author":"Boisen","year":"1978","journal-title":"Acta Neurol Scand"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12883-018-1149-6","article-title":"Comorbidity of migraine with ADHD in adults","volume":"18","author":"Hansen","year":"2018","journal-title":"BMC Neurol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1089\/cap.2022.0038","article-title":"Guanfacine for the treatment of attention-deficit hyperactivity disorder: an updated systematic review and meta-analysis","volume":"33","author":"Yu","year":"2023","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3109\/07853899709002452","article-title":"Molecular pharmacology of alpha 2-adrenoceptor subtypes","volume":"27","author":"Aantaa","year":"1995","journal-title":"Ann Med"},{"key":"ref51","year":"2026"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1947051\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:33:21Z","timestamp":1789623201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1947051\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":51,"alternative-id":["10.3389\/fneur.2026.1947051"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1947051","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1947051"}}